Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Revenue | $8.0K | $0 | $0 | $0 |
| Cost of revenue | $12.7K | $351.0K | $479.0K | $1.4M |
| Gross profit | −$4.7K | −$351.0K | −$479.0K | −$1.4M |
| Gross margin | -58.6% | — | — | — |
| R&D | $12.8M | $16.8M | $31.0M | $34.6M |
| Operating income | −$16.1M | −$20.9M | −$42.3M | −$48.2M |
| EBITDA | −$15.9M | −$20.6M | −$41.8M | −$46.1M |
| Net income | −$15.0M | −$20.8M | −$41.6M | −$44.0M |
| Net margin | -188050.0% | — | — | — |
| EPS (diluted) | -0.77 | -0.87 | -1.18 | -1.25 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds CYT.
No tracked institution reports a position in CYT as of their last filing.
| Execution date | Ratio |
|---|---|
| 2014-09-18 | 2-for-1 |
No one on the platform has traded CYT yet.
| $105M |
| — |
| JNCEJounce Therapeutics, Inc. | $1.88 | +0.00% | $99M | — |
| KNTEKinnate Biopharma Inc. | $2.65 | -0.38% | $125M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.